Renibus Therapeutics Inc.

ReCode Therapeutics , on track with its plan to take its two lead programs into the clinic this year, announced on 19 September that it raised another $50m in series B venture capital, bringing the ro

US FDA’s flagship expedited review programs – the breakthrough therapy designation and its younger cousin, the biologics-focused regenerative medicine advanced therapy designation – have added new des

Venture capital investors showed biopharmaceutical start-ups and growth-stage private companies some love with a trio of $100m-plus financings announced on 14 and 16 February, including a $236m series

In two initiatives intended to increase the transparency of its coronavirus activities, the European Medicines Agency has published the clinical data that was used to support the EU marketing authoriz